Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Colon Cancer. According to GlobalData, Phase II drugs for Colon Cancer have an 11% phase transition success ...
For example, if harmful bacteria in the mouth cause damage there, they can potentially spread to other parts of the body and harm tissues elsewhere. This connection could explain why poor oral ...